Research Topics
Species | Francisco CervantesSummaryCountry: Spain Publications
| Collaborators
|
Detail Information
Publications
New and old treatment modalities in primary myelofibrosisFrancisco Cervantes
Hematology Department, Hospital Clinic, IDIBAPS, University of Barcelona, Spain
Cancer J 13:377-83. 2007..Newer immunomodulatory drugs, proteasome inhibitors, hypomethylating agents, and JAK2 inhibitors are currently being tested...- Epigenetic regulation of human cancer/testis antigen gene, HAGE, in chronic myeloid leukemiaJose Roman-Gomez
Hematology Department, Reina Sofia Hospital, Avda Menendez Pidal s n 14004 Cordoba, Spain
Haematologica 92:153-62. 2007..To date, CTA genes have been shown to be expressed in a range of solid tumors via demethylation of their promoter CpG islands, but rarely in chronic myeloid leukemia (CML) or other hematologic malignancies... - Epigenetic regulation of PRAME gene in chronic myeloid leukemiaJose Roman-Gomez
Hematology Department, Reina Sofia Hospital, Avda, Menendez Pidal s n, 14004, Cordoba, Spain
Leuk Res 31:1521-8. 2007..0001). These results suggest that hypomethylation of PRAME up-regulates its expression in CML and might play a significant role in the progression of the disease... - Repetitive DNA hypomethylation in the advanced phase of chronic myeloid leukemiaJose Roman-Gomez
Hematology Department, Reina Sofia Hospital, Avda Menendez Pidal s n, 14004 Cordoba, Spain
Leuk Res 32:487-90. 2008..Furthermore, a more profound level of hypomethylation was observed among BC samples compared with CP samples. Our data suggest that repetitive DNA hypomethylation are closely associated with CML progression... 
Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemiaMargherita Maffioli
Hematology Department, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
Leuk Res 35:1014-9. 2011..Beside, the MDR1 haplotype 1236T-2677G-3435C was more frequently found in patients primarily resistant to imatinib...- Increased platelet, leukocyte, and coagulation activation in primary myelofibrosisAlberto Alvarez-Larran
Hematology Department, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
Ann Hematol 87:269-76. 2008..In conclusion, PMF patients have platelet, leukocyte, endothelial, and coagulation activation similar to that in PV and ET. CD11b overexpression and F1 + 2 are correlated with the presence of the JAK2 mutation... - Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burdenEduardo Arellano-Rodrigo
Hematology Department, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
Am J Hematol 84:102-8. 2009.... - Darbepoetin-alpha for the anaemia of myelofibrosis with myeloid metaplasiaFrancisco Cervantes
Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
Br J Haematol 134:184-6. 2006..006). None of the patients with appropriate serum erythropoietin levels responded. Treatment was usually well tolerated... - Improving survival trends in primary myelofibrosis: an international studyFrancisco Cervantes
Hospital Clinic, Institut d Investigacio Biomedica August Pi i Sunyer, University of Barcelona, Spain
J Clin Oncol 30:2981-7. 2012..This study was aimed at ascertaining whether survival prolongation has actually occurred in PMF... - Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemiaAlberto Alvarez-Larran
Hematology Department, Hospital del Mar, Barcelona, Spain
Blood 116:1205-10; quiz 1387. 2010..In the remaining low-risk patients, this therapy is not effective as primary prophylaxis of thrombosis, and observation may be an adequate option... 
Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA groupFrancisco Cervantes
Hematology Department, Hospital Clinic, Villarroel 170, 08036 Barcelona, Spain
Haematologica 95:1317-24. 2010..Despite the favorable results of imatinib front line in chronic-phase chronic myeloid leukemia there is room for improvement...- Automated assessment of the neutrophil and platelet activation status in patients with essential thrombocythemiaEduardo Arellano-Rodrigo
Department of Hemotherapy and Hemostasis, University of Barcelona, Barcelona, Spain
Platelets 23:336-43. 2012..The intensity of the agreement between the variables obtained by the two methods was moderate. These results support the possible value of MPC as surrogate parameter of platelet activation in ET... - Prognostication in primary myelofibrosisFrancisco Cervantes
Hematology Department, Hospital Clinic, IDIBAPS, University of Barcelona, Villarroel 170, Barcelona, Spain
Curr Hematol Malig Rep 7:43-9. 2012.... - Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemiaJose Roman-Gomez
Hematology Department, Reina Sofia Hospital, Avda Menendez Pidal s n 14004, Cordoba, Spain
Oncogene 24:7213-23. 2005..005). The above results strongly suggest that activation of both sense and antisense transcriptions by aberrant promoter hypomethylation of the L1 elements plays a role in the progression and clinical behavior of the CML... - Myelofibrosis with myeloid metaplasia: diagnosis, prognostic factors, and stagingFrancisco Cervantes
Hematology Department, , IDIBAPS, Barcelona, Spain
Semin Oncol 32:395-402. 2005..Such a staging system should be derived from a large population of patients, systematically collected from diagnosis without selection bias and followed over time... - Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational statusEduardo Arellano-Rodrigo
Hematology Department, , Villarroel 170, 08036 Barcelona, Spain
Haematologica 91:169-75. 2006..INTERPRETATION AND CONCLUSIONS: These results would support a role for platelet and monocyte activation in the thrombosis of ET. In these patients, the presence of the JAK2 V617F mutation is associated with higher platelet activation... - Survivin expression in the progression of chronic myeloid leukemia: a sequential study in 16 patientsJuan Carlos Hernández-Boluda
Hematology Department, Institute of Hematology and Oncology, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
Leuk Lymphoma 46:717-22. 2005..However, further studies are required to elucidate the possible prognostic importance of such biological findings in this disease... - Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patientsAlejandra Martínez-Trillos
Hematology Department, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
Ann Hematol 89:1233-7. 2010..HU is an effective and generally well-tolerated therapy for the hyperproliferative manifestations of MF. The accentuation of the anemia often induced by HU is usually manageable with concomitant treatment... - Management of essential thrombocythemiaFrancisco Cervantes
Hematology Department, Hospital Clinic, University of Barcelona, Barcelona, Spain
Hematology Am Soc Hematol Educ Program 2011:215-21. 2011..Strict control of coexistent cardiovascular risk factors is mandatory for all patients. The role in ET therapy of new drugs such as pegylated IFN or the JAK2 inhibitors is currently under investigation... - Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patientsFrancisco Cervantes
Haematology Department, Hospital Clinic, IDIBAPS, University of Barcelona, Spain
Br J Haematol 129:771-5. 2005..001) and higher Hb at treatment start (P= 0.02). Toxicity was usually moderate, leading to treatment withdrawal in only two cases. Danazol is effective and well tolerated in a substantial proportion of MMM patients with anaemia... - Advances in the understanding and management of primary myelofibrosisFrancisco Cervantes
Hematology Department, IDIBAPS, University of Barcelona, Barcelona, Spain
Curr Opin Oncol 23:665-71. 2011..We herein review the recent contributions to the understanding and management of PMF... - New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and TreatmentFrancisco Cervantes
Hematology Department, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
Blood 113:2895-901. 2009..JAK2V617F did not cluster with a specific risk group or affect survival... - Modern management of myelofibrosisFrancisco Cervantes
Haematology Department, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
Br J Haematol 128:583-92. 2005..The next candidates for the treatment of myelofibrosis are the thalidomide derivatives, the proteasome inhibitors, and vascular endothelial growth factor neutralizing antibodies... - Idiopathic myelofibrosis associated with classic polyarteritis nodosaMireia Camos
Institute of Hematology and Oncology, Department of Hematology, Postgraduate School of Hematology Farreras Valenti, Hospital Clinic, Villarroel 170, University of Barcelona, Barcelona, 08036 Spain
Leuk Lymphoma 44:539-41. 2003..This case represents a new association between IM and an autoimmune disease and supports the hypothesis of an immune basis of IM in some patients... - Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patientsFrancisco Cervantes
Haematology Department, Institute of Haematology and Oncology, Hospital Clinic, IDIBAPS, University of Barcelona, Spain
Br J Haematol 118:786-90. 2002..After a median the myelofibrotic transformation, three patients have died and four have not required treatment for MMM as yet... - Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literatureFrancisco Cervantes
Haematology Department, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
Br J Haematol 127:399-403. 2004..In the multivariate analysis, serum erythropoietin level <125 U/l was found to be associated with a favourable response to rHuEPO, whereas lack of transfusional support had borderline significance... - Imatinib mesylate (STI571) treatment in patients with chronic-phase chronic myelogenous leukaemia previously submitted to autologous stem cell transplantationFrancisco Cervantes
Haematology Department, Hospital Clinic, IDIBAPS, Barcelona, Spain
Br J Haematol 120:500-4. 2003..Imatinib mesylate is effective and safe in chronic-phase CML patients with a previous history of intensive treatment... - Cadherin-13, a mediator of calcium-dependent cell-cell adhesion, is silenced by methylation in chronic myeloid leukemia and correlates with pretreatment risk profile and cytogenetic response to interferon alfaJose Roman-Gomez
Hematology Department, Reina Sofia Hospital, Avda, Menendez Pidal s n, 14004 Cordoba, Spain
J Clin Oncol 21:1472-9. 2003..Although defective progenitor-stromal adhesion is a well-recognized feature of chronic myeloid leukemia (CML), the role of CDH13 abnormalities has not been evaluated in this disease... - Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemiaMonica Pou
Nephrology Department, , Barcelona, Spain
Leuk Lymphoma 44:1239-41. 2003..One year later the patient still has mild chronic renal failure and remains in chronic phase of CML on hydroxyurea treatment... - Five-year follow-up of patients receiving imatinib for chronic myeloid leukemiaBrian J Druker
Oregon Health and Science University Cancer Institute, L592, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA
N Engl J Med 355:2408-17. 2006..Imatinib inhibits this kinase, and in a short-term study was superior to interferon alfa plus cytarabine for newly diagnosed CML in the chronic phase. For 5 years, we followed patients with CML who received imatinib as initial therapy... - Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research andRuben A Mesa
Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Leuk Res 31:737-40. 2007.... - Imatinib mesylate (Gleevec, Glivec): a new therapy for chronic myeloid leukemia and other malignanciesJuan Carlos Hernández-Boluda
Hematology and Medical Oncology Department, Hospital Clinico Universitario, Valencia, Spain
Drugs Today (Barc) 38:601-13. 2002..In this sense, it must be pointed out that imatinib has shown a remarkable activity in gastrointestinal stromal tumors... - Idiopathic myelofibrosis associated with ulcerative colitisEduardo Arellano-Rodrigo
Institute of Hematology and Oncology, Department of Hematology, Postgraduate School of Hematology Farreras-Valent, Barcelona, Spain
Leuk Lymphoma 43:1481-3. 2002..The present case represents a new association of IM with an autoimmune disease and gives support to the hypothesis of a possible immune basis of some IM cases... - Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemiaStephen G O'Brien
University of Newcastle, Newcastle, United Kingdom
N Engl J Med 348:994-1004. 2003..We compared the efficacy of imatinib with that of interferon alfa combined with low-dose cytarabine in newly diagnosed chronic-phase CML... - Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET)Giovanni Barosi
Laboratorio di Epidemiologia Clinica, IRCCS Policlinico S Matteo, Viale Golgi 19, 27100 Pavia, Italy
Blood 106:2849-53. 2005..A histologic response was defined by changes in bone marrow fibrosis and cellularity grades. The combined use of these response definitions should help standardize the design and reporting of future clinical studies in MMM... - Myelofibrosis with myeloid metaplasia: disease overview and non-transplant treatment optionsRuben A Mesa
Laboratory of Clinical Epidemiology, IRCCS Policlinico S Matteo, Pavia, Italy
Best Pract Res Clin Haematol 19:495-517. 2006..Modern therapy remains palliative but allogeneic stem cell transplantation might be curative to a selected group of patients. This chapter reviews both the old and the new therapy with regard to non-transplant treatment options for MMM... - Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panelAyalew Tefferi
Mayo Clinic, Rochester, MN 55905, USA
Blood 110:1092-7. 2007.... - Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intoleranceHagop M Kantarjian
Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1402, USA
Blood 110:3540-6. 2007..In summary, nilotinib is highly active and safe in patients with CML-CP after imatinib failure or intolerance. This clinical trial is registered at http://clinicaltrials.gov as ID no. NCT00109707... - Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNetMichele Baccarani
Department of Hematology Oncology L and A Seràgnoli, S Orsola Malpighi Hospital, Via Massarenti 9, 40138 Bologna, Italy
Blood 108:1809-20. 2006..The importance of regular monitoring at experienced centers was highlighted... - International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)Ayalew Tefferi
Mayo Clinic, 200 First Street SW, Rochester MN 55905, USA
Blood 108:1497-503. 2006..Bone marrow histologic and hematologic remissions characterize CR and CR/PR, respectively. The panel agreed that the CI response category is applicable only to patients with moderate to severe cytopenia or splenomegaly... - Portal hypertension secondary to myelofibrosis: a study of three casesAlberto Alvarez-Larran
Hematology Department, Azienda Ospedaliero Universitaria di Careggi, Firenze, Italy
Am J Gastroenterol 100:2355-8. 2005..In patients with idiopathic myelofibrosis (IM), portal hypertension (PHT) without thrombosis of the hepatic or splenoportal veins is infrequent... - JAK2 exon 12 mutations in polycythemia vera or idiopathic erythrocytosisLuz Martínez-Avilés
Department of Pathology, Hospital del Mar, IMAS, Barcelona, Spain
Haematologica 92:1717-8. 2007..Initial hematologic data of these patients differ from those of V617F-positive patients, but there is no difference in thrombotic development and myelofibrotic transformation... - Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemiaStephanie J Lee
Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Blood 112:3500-7. 2008..Acute graft-versus-host disease rates were similar between IM(+) and IM(-) groups regardless of leukemia phase. These results should be reassuring to patients receiving IM before HCT... - Late response to donor lymphocyte infusions in patients with chronic myeloid leukemia relapsing after allogeneic stem cell transplantationMarta Gomez
Haematologica 87:1003-5. 2002..The median time (range) in months to achieve a hematologic, cytogenetic and molecular remission was 2 (1-2), 5 (1-42) and 5 the median response duration is 16 months (range 1-36), and no patient shows evidence of relapse...